Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic Syndromes
全基因组测序用于骨髓增生异常综合征患者的基因组评估和风险分层
基本信息
- 批准号:10506155
- 负责人:
- 金额:$ 26.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAffectAlgorithmsAneuploidyAspirate substanceBiological AssayBone MarrowBone Marrow CellsBone Marrow DiseasesBone marrow failureCLIA certifiedCharacteristicsChromosome DeletionChromosome abnormalityClinicalClinical TrialsClinical assessmentsCytogenetic AnalysisCytogeneticsDNA Sequence AlterationDetectionDiagnosisDiagnosticDisadvantagedDiseaseDysmyelopoietic SyndromesEnrollmentEvaluationEventFailureFrequenciesFutureGeneticGenetic RiskGenomicsGoalsInformaticsInterventionKaryotype determination procedureLaboratoriesLoss of HeterozygosityMalignant NeoplasmsMarrowMetaphaseMethodsMorbidity - disease rateMutationMyeloproliferative diseaseNatural HistoryOutcomePatientsPerformancePersonsPrecision therapeuticsProspective cohortResolutionRiskRisk AssessmentSamplingSecondary acute myeloid leukemiaSecondary toStem cell transplantTestingVariantaggressive therapyclinically relevantcohortdetection limitgene panelgenetic profilinggenetic risk assessmentgenome sequencinghuman old age (65+)improvedin silicomortalitypatient stratificationpredict clinical outcomeprediction algorithmprognosticprospectiveresearch clinical testingrisk predictionrisk stratificationsuccesstumorwhole genome
项目摘要
The goal of this proposal is to improve genetic profiling and risk stratification for patients with
myelodysplastic syndromes (MDS) using clinical whole-genome sequencing. MDS is a heterogenous
group of clonal bone marrow disorders that are often fatal due to marrow failure or progression to acute myeloid
leukemia (AML). Accurate prediction progression risk is therefore critical for the management of MDS patients
in order to prolong survival and minimize the potential for morbidity and mortality associated with more
aggressive treatments. Cytogenetic analysis of bone marrow cells from MDS patients via metaphase karyotyping
is an essential component of MDS risk assessment algorithms, and is used to detect chromosomal deletions,
duplications, and aneuploidies that are associated with differential clinical outcomes. Although karyotyping has
been used effectively for decades, it has several disadvantages. These include low genomic resolution and high
failure rates that can result in incomplete genetic risk profiles for some patients. We recently developed and
validated ChromoSeq, a robust CAP/CLIA-compliant whole-genome sequencing (WGS) assay for genetic
profiling of patients with myeloid malignancies. We showed that this method was 100% sensitivity for clinically
relevant cytogenetic abnormalities in AML and identified additional cytogenetic events in up to 25% of patients
that were not detected by standard cytogenetics. These findings included new risk-defining chromosomal
abnormalities in almost 15% of patients, which resulted in better prediction of clinical outcomes. Although MDS
and AML are closely related diseases that share many features, the genomic characteristics and cellular
composition of MDS is distinct. In addition, the use of ChromoSeq results to form existing MDS risk groups has
not been clinically validated. We hypothesize that optimization of the ChromoSeq whole-genome
sequencing assay for MDS samples will improve the accuracy of genetic profiling and risk stratification
of MDS patients. Here we propose to use a combination of retrospective and prospective clinical MDS samples
to validate ChromoSeq for genetic profiling and risk assessment in MDS patients. We will first use retrospective
MDS samples to optimize and validate our existing CAP/CLIA-compliant ChromoSeq WGS assay to improve the
detection of low frequency mutations, copy number alterations (CNAs) and copy neutral loss of heterozygosity
(CNLOH), which are common in MDS (Aim 1; UH2 component). We will then use a prospective MDS cohort to
establish the clinical validity of ChromoSeq assay for genomic profiling and risk assessment of MDS patients.
This project will expand the use of the CAP/CLIA-compliant ChromoSeq assay to MDS samples so that it may
be used for future interventional clinical trials and routine clinical testing of patients with this malignancy.
该建议的目的是改善遗传谱和风险分层的患者
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERIC J DUNCAVAGE其他文献
ERIC J DUNCAVAGE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERIC J DUNCAVAGE', 18)}}的其他基金
Genome sequencing for evaluating the efficacy, specificity, and safety of human genome editing
用于评估人类基因组编辑的有效性、特异性和安全性的基因组测序
- 批准号:
10667893 - 财政年份:2023
- 资助金额:
$ 26.15万 - 项目类别:
A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung Cancer
肺癌临床基因组分析的快速综合方法
- 批准号:
10613055 - 财政年份:2023
- 资助金额:
$ 26.15万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 26.15万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 26.15万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 26.15万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 26.15万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 26.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 26.15万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 26.15万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 26.15万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 26.15万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 26.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




